SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     




J Nucl Med. 2009; 50 (Supplement 2):36
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Pfost, B.
Right arrow Articles by Senekowitsch-Schmidtke, R.
PubMed
Right arrow Articles by Pfost, B.
Right arrow Articles by Senekowitsch-Schmidtke, R.

Radiopharmaceutical Chemistry: Dosimetry/ISRTRD Alpha Symposium

ISRTRD/ALPHA Session1: Clinical & Pre-clinical Studies

Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAb

Birgit Pfost1, Alfred Morgenstern2, Christof Seidl1, Frank Bruchertseifer2, Michael Autenrieth3, Christos Apostolidis2, Kamel Abbas4 and Reingard Senekowitsch-Schmidtke1

1 Dept. Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany 2 EC, JRC, Inst. Transuranium Elements, Karlsruhe, Germany 3 Dept. Urology, Technische Universitaet Muenchen, Munich, Germany 4 EC, JRC, Inst. Health Consumer Protect., Ispra, Italy

36

Objectives: Transurethral resection of urothelial cancer still results in high recurrence rates. In new concepts for therapy of disseminated tumor cells {alpha}-emitter immunoconjugates are applied. Therefore the aim of this study was to compare the therapeutic efficacy of Bi-213- and Th-226-anti-EGFR-MAb in an orthotopic EGFR-overexpressing bladder carcinoma model.

Methods: 2x106 luciferase transfected EJ28 cancer cells were instilled into the bladders of female swiss nu/nu mice following urothelial electrocautery. 10 tumor-bearing mice each were intravesically instilled with 0.925 MBq of Bi-213-MAb or 0.37 MBq Th-226-MAb 1h, 7d and 14d after cell inoculation; controls received PBS. Tumor development and therapy response was imaged via bioluminescence imaging and survival observed up to 300d.

Results: Mice of the control group reached a median survival of 41d. Bi-213-anti-EGFR therapy prolonged survival >300 d in 90%, 80% and 40% of animals treated 1h, 7d and 14d after cell instillation, respectively. Therapy with Th-226-MAb starting 10/2008 turned out to be as effective as Bi-213 therapy: 90% of animals of each group treated 1h, 7d and 14 d after cell inoculation are still alive without signs of toxicity.

Conclusions: Both {alpha}-emitter-anti-EGFR conjugates effectively eradicated disseminated tumor cells.Thus, therapy using Th-226-anti-EGFR might be a very promising supplement and/or alternative to Bi-213-anti-EGFR in treatment of urothelial cancer.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Pfost, B.
Right arrow Articles by Senekowitsch-Schmidtke, R.
PubMed
Right arrow Articles by Pfost, B.
Right arrow Articles by Senekowitsch-Schmidtke, R.